Antipsychotic drugs are central to the treatment of schizophrenia and other psychotic
disorders but are ineffective for some patients and associated with side-effects and …

Schizophrenia is a debilitating illness with a lifetime prevalence estimate of 0.6% and
consists of symptoms from the positive, negative, and cognitive domains. Social support …

The American Psychiatric Association Practice Guideline for the Treatment of Patients With
Schizophrenia seeks to reduce these substantial psychosocial and public health …

Abstract Treatment-resistant schizophrenia (TRS) will affect about one in three patients with
schizophrenia. Clozapine is the only treatment approved for TRS, and patients should be …

According to current evidence and guidelines, continued antipsychotic treatment is key for
preventing relapse in people with schizophrenia‐spectrum disorders, but evidence‐based …

Negative symptoms of schizophrenia remain a major therapeutic challenge. The progress in
the conceptualization and assessment is not yet fully reflected by treatment research …

Importance Antipsychotic drugs (particularly clozapine) have been associated with
pneumonia in observational studies. Despite studies of the associations between …

These updated guidelines from the British Association for Psychopharmacology replace the
original version published in 2011. They address the scope and targets of pharmacological …

Background Evidence for the management of inadequate clinical response to clozapine in
treatment-resistant schizophrenia is sparse. Accordingly, an international initiative was …

Abstract About 40%-70% of the patients with treatment-resistant schizophrenia have a poor
response to adequate treatment with clozapine. The impact of clozapine-resistant …